Nosocomial fungal infections have increased in incidence over the last two decades, reflecting an ever increasing population of vulnerable patients, ranging from very low birthweight infants to solid organ transplant recipients. Optimal methods for the prevention of these infections have been the focus of considerable attention, but many questions remain unanswered.Candida species are numerically the major cause of nosocomial fungal infections. Although candidiasis is often due to an endogenous source, erogenous infection is now well recognised, with cross infection between patients occurring in the intensive care unit setting. Prevention requires rigorous handwashing in high-risk areas, in addition to surveillance and aggressive investigation of outbreaks.Prevention of nosocomial aspergillosis poses complex challenges. Aspergillus spores are inhaled: unfiltered outside air contains an average of 1- 15 pathogenic Aspergillus sp. colony-forming units per cubic metre, with marked short-term fluctuations and also seasonal variation in counts. An association between outbreaks of aspergillosis and construction work on or near hospital sites has been repeatedly reported. Published recommendations such as the revised CDC Guidelines for prevention of nosocomial pneumonia (1997) detail measures to protect vulnerable patients: but how much protection is needed for which patients? What can we learn from recent molecular epidemiological studies? Some of the quandaries in this area will be discussed.
Full conference title:
5th Trends in Invasive and Fungal Infections
- TIFI 5th